PubMed
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
Attie KM, Borgstein NG, Yang Y, et al. Muscle Nerve. 2013
Healing & RecoveryResearch Only — Development HaltedC
ACE-031
Ramatercept / ActRIIB-Fc
ACE-031 (ramatercept) is a soluble ActRIIB-Fc fusion protein that traps myostatin and related TGF-β superfamily ligands to disinhibit muscle growth. Phase 1 healthy-volunteer data showed lean-mass and thigh-muscle volume increases, and Phase 2 work explored Duchenne muscular dystrophy — but clinical development was discontinued after bleeding-related adverse events (epistaxis, telangiectasias) linked to off-target BMP9 inhibition. Not FDA-approved; extreme caution.
Last reviewed . First published . By the PeptIQ team.
Observational report only — modeled community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 8
- Research grade
- C
- Experience
- 76
- Activity
- 43
Overall check-ins
Trackers & reports
Overview
About ACE-031
ACE-031 (ramatercept) is a soluble ActRIIB-Fc fusion protein that traps myostatin and related TGF-β superfamily ligands to disinhibit muscle growth. Phase 1 healthy-volunteer data showed lean-mass and thigh-muscle volume increases, and Phase 2 work explored Duchenne muscular dystrophy — but clinical development was discontinued after bleeding-related adverse events (epistaxis, telangiectasias) linked to off-target BMP9 inhibition. Not FDA-approved; extreme caution.
- Category
- Healing & Recovery
- Regulatory status
- Research Only — Development Halted
- Also known as
- Ramatercept / ActRIIB-Fc
- Self-reports
- 308
Community
What 308 users report
308 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 62% · Mixed 22% · Unfavorable overall 16%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Joint comfort
-149
Recovery
-31
Digestive comfort
-151
Skin appearance
-99
Appetite control
-47
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site reaction
-53
Anxiety
-132
Flushing
-6
Headache
-103
GI discomfort
-48
Self-reported dose per injection
Median bucket: 200–400 mcg · Most common: 100–200 mcg
Reports span 25–1000 mcg
25–50
4
50–100
14
100–200
18
200–400
9
400–600
6
600–1000
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Common discussion topics
timing32stacking10side effects28ace-03116
How repeat users are trending
Among repeat reporters, 57% said they felt similar to their last entry, 30% more positive, and 12% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 28 days · Based on 68 repeat reporters
Community charts use modeled aggregates when live Supabase snapshots are unavailable.
Research
Sources (4)
- Wiki study page →Source
- Wiki study page →Source
PubMed
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
Campbell C, McMillan HJ, Mah JK, et al. Muscle Nerve. 2017
- Wiki study page →Source
PubMed
Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig MH, Ahmad K, Moon JS, et al. Front Physiol. 2022
- Wiki study page →Source
ClinicalTrials.gov
ACE-031 (ActRIIB-Fc) studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
Tools
Explore more
Explore
More ways to learn about ACE-031 from observational PeptIQ data.
Related peptides
Help
Frequently asked
What do PeptIQ users report about ACE-031?
This page summarizes 308 anonymized self-reports from PeptIQ users who track ACE-031, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for ACE-031?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for ACE-031?
4 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is ACE-031 safe to use?
This wiki does not assess safety or recommend use. ACE-031 is listed as Research Only — Development Halted. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of ACE-031?
This wiki summarizes observational community reports and linked citations for ACE-031. It does not assert therapeutic benefits. See the sources list on this page and the educational profile for ACE-031 for study-level context — not medical advice.
What is the legal status of ACE-031?
ACE-031 is listed in PeptIQ as Research Only — Development Halted. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of ACE-031?
Safety data quality for ACE-031 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on ACE-031?
This page links 4 sources for ACE-031. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.